Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.300
-0.080 (-3.36%)
Jun 29, 2026, 4:00 PM EDT - Market closed

Grace Therapeutics Stock Forecast

Stock Price Forecast

According to 2 analysts polled by S&P Global, Grace Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.95. The average 1-year stock price forecast is 158.70% higher than the current stock price, while the lowest is $3.99 (+73.48%) and the highest is $7.90 (+243.48%).

Price Target: $5.95 (+158.70%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$3.99$5.95$5.95$7.90
Change+73.48%+158.70%+158.70%+243.48%

Analyst Ratings

The average analyst rating for Grace Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJun '25Aug '25Nov '25Feb '26Apr '26Jun '26
Strong Buy222222
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total222222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Craig-Hallum
Craig-Hallum
Buy
Reiterates
$4
BuyReiterates$4+73.91%Jun 22, 2026
TD Cowen
TD Cowen
Buy
Reiterates
$12$8
BuyReiterates$12$8+247.83%Apr 23, 2026

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
5.51M
EPS This Year
-0.52
from -0.46
EPS Next Year
-0.55
from -0.52
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingMar 31, 2022Mar 31, 2023Mar 31, 2024Mar 31, 2025Mar 31, 2026Mar 31, 2027
Revenue
------
Operating Income
-12.14M-18.21M-11.28M-16.68M-11.08M-8.98M
Net Income
-9.82M-42.43M-12.85M-9.57M-7.79M-8.98M
EPS
-----0.46-0.52
Free Cash Flow
-4.57M-9.06M-7.40M-9.01M-5.73M-8.18M
No. Analysts
-----2
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202720282029
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20282029
High-
Avg-
Low-

EPS Forecast

EPS202720282029
High-0.52
Avg-0.52
Low-0.52

EPS Growth

EPS Growth202720282029
High-
Avg-
Low-